SNGX

Soligenix is a pre-revenue, clinical-stage biopharma with no approved products, and its own FY2025 10-K carries an explicit going-concern paragraph: management states its losses, negative cash flows, and shareholders' deficit 'raise substantial doubt about our ability to continue as a going concern' absent new debt or equity financing within a year. That is the whole story. The 'revenue' the P/S multiple of 33x is built on is a rounding error — $119K in FY2024, down 85.8% YoY, and the historical top line ($824K in FY2021 down to nothing) is grant/contract funding, not product sales. The MD&A confirms the company does 'not expect to generate any revenues from product sales in the foreseeable future, if at all.'

The balance sheet cannot support the burn. Cash of $7.94M against operating cash outflow of -$10.3M in FY2025 (worsening 22.2% YoY) implies well under a year of runway. R&D spending is rising (+43.3% to $7.49M) to fund the FLASH2 confirmatory Phase 3, so the cash need is structural, not discretionary. The only way this company has stayed alive is issuing stock — shares outstanding exploded 226.6% in a single year to 10.3M, and that dilution is guaranteed to continue and to compound whatever a shareholder owns today. Retained deficit sits at -$245M against $5.29M of equity: 39 years of accumulated losses with nothing commercialized.